CD171抗体;CD171 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of THP-1 cells using CD171 mouse mAb (green) and negative control (red).    

  
  

CD171. also known as L1 cell adhesion molecule (L1CAM), is a transmembrane glycoprotein belonging to the immunoglobulin (Ig) superfamily. It plays critical roles in neural development, including axon guidance, neuronal migration, and synaptic plasticity, mediated through homophilic and heterophilic interactions. Beyond the nervous system, CD171 is aberrantly expressed in various cancers, such as neuroblastoma, melanoma, and ovarian carcinoma, where it promotes tumor progression, metastasis, and therapy resistance by enhancing cell adhesion, survival, and invasion.

CD171 antibodies are tools developed to target this molecule for research and therapeutic purposes. In research, they are widely used in immunohistochemistry, flow cytometry, and functional studies to explore CD171's biological roles and its association with malignancies. Therapeutically, anti-CD171 antibodies have been investigated as potential agents for antibody-drug conjugates (ADCs) or immunotherapies, leveraging their ability to specifically bind cancer cells expressing CD171. For instance, preclinical studies in neuroblastoma have shown promising results by delivering cytotoxic payloads directly to CD171-positive tumor cells.

Challenges include optimizing antibody specificity to minimize off-target effects and overcoming variable CD171 expression across tumor subtypes. Despite this, CD171 remains a compelling target due to its restricted normal tissue expression and strong link to aggressive cancer phenotypes. Ongoing research aims to refine antibody engineering and explore combinatorial therapies to enhance clinical efficacy.